rosiglitazone has been researched along with Uremia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chernichovski, T; Filip, I; Ingbir, M; Levin-Iaina, N; Levo, Y; Reshef, R; Rozovski, U; Schwartz, D; Schwartz, IF; Shtabsky, A | 1 |
| Bhandari, S; Semple, DJ; Seymour, AM | 1 |
| Chow, KM; Lam, CW; Leung, CB; Li, PK; Szeto, CC; Wong, TY | 1 |
| Scherbaum, WA | 1 |
1 trial(s) available for rosiglitazone and Uremia
| Article | Year |
|---|---|
Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.
Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain | 2005 |
3 other study(ies) available for rosiglitazone and Uremia
| Article | Year |
|---|---|
Rosiglitazone improves aortic arginine transport, through inhibition of PKCalpha, in uremic rats.
Topics: Animals; Aorta; Arginine; Biological Transport; Cationic Amino Acid Transporter 1; Disease Models, Animal; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Nitric Oxide; Protein Kinase C-alpha; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Uremia | 2008 |
Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Uremia | 2012 |
Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?
Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain | 2006 |